BACKGROUND: @entity299 ( @entity299 ) include @entity6015 and @entity296 . Several candidate biomarkers were evaluated in cases at risk for @entity299 on the basis of potential roles in @entity32 , @entity82 , and @entity299 : @entity1851 ( @entity1851 ); NT-pro-B-type natriuretic peptide (NT-proBNP); troponin I; @entity1476 ; @entity2290 ( @entity2290 ); @entity10431 ( @entity10431 ); plasminogen; and @entity560 . OBJECTIVES: Identification of maternal and fetal biomarkers associated with development and morbidity of @entity299 should provide clues to pathogenesis with translational implications for management. METHODS: Cord (139) and maternal (135) blood samples collected during pregnancies at risk for @entity299 were available for study. Levels of cord and maternal @entity1851 , cord NT-proBNP, and cord troponin I were evaluated using multiplex assays. Cord and maternal @entity560 were assessed by liquid chromatography-mass spectrometry. @entity1476 , @entity2290 , @entity10431 , and plasminogen were evaluated using ELISA. RESULTS: Cord @entity1851 , NT-proBNP, @entity1476 , @entity2290 , @entity10431 , and plasminogen levels were higher in @entity299 -affected fetuses than in unaffected cases, independent of maternal @entity627 , season at highest risk of @entity299 development, and medications taken during pregnancy. These biomarkers were positively associated with a disease severity score derived from known risk factors for mortality in @entity299 . Maternal @entity1851 and cord troponin I levels did not differ between the groups. Cord and maternal @entity560 levels were not significantly associated with @entity299 , but average maternal @entity560 level during pregnancy was positively associated with longer time to postnatal pacemaker placement. CONCLUSIONS: These data support the association of fetal reactive inflammatory and fibrotic components with development and morbidity of @entity299 . Following @entity1851 and NT-proBNP levels after birth can potentially monitor severity and progression of @entity299 . @entity1476 and the @entity2290 / @entity10431 /plasminogen cascade provide therapeutic targets to decrease @entity82 . Although decreased @entity560 did not confer increased risk, given the positive influence on postnatal outcomes, maternal levels should be optimized.

Serum Biomarkers of @entity32 , XXXX , and Cardiac Function in Facilitating Diagnosis, Prognosis, and Treatment of Anti-SSA/Ro-Associated Cardiac Neonatal Lupus.

@entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis'] @entity296 :: ('MESH:D009202', 'Disease') :: ['cardiomyopathy'] @entity10431 :: ('5329', 'Gene') :: ['uPAR', 'urokinase plasminogen activator receptor'] @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic disease'] @entity1476 :: ('4313', 'Gene') :: ['matrix metalloproteinase (MMP)-2', 'MMP-2'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac NL', 'Cardiac manifestations of neonatal lupus', 'cardiac dysfunction'] @entity6015 :: ('MESH:C535758', 'Disease') :: ['congenital heart block'] @entity2290 :: ('5328', 'Gene') :: ['urokinase plasminogen activator', 'uPA'] @entity560 :: ('MESH:D014807', 'Chemical') :: ['vitamin D'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity82 :: (MESH:D005355,Disease) :: ['Fibrosis']
